
Talus Bio turns previously undruggable transcription factors into therapeutic targets by directly measuring and modulating the cellular regulome. The company’s MARMOT platform combines functional proteomics, automated biology, synthetic chemistry, and machine learning to generate large-scale functional datasets in living human cells and design candidate molecules. Talus Bio focuses on drug discovery for oncology and other diseases driven by genome regulators, including autoimmunity and neurodegeneration. The company partners with pharmaceutical and biotechnology organizations to advance therapeutics.

Talus Bio turns previously undruggable transcription factors into therapeutic targets by directly measuring and modulating the cellular regulome. The company’s MARMOT platform combines functional proteomics, automated biology, synthetic chemistry, and machine learning to generate large-scale functional datasets in living human cells and design candidate molecules. Talus Bio focuses on drug discovery for oncology and other diseases driven by genome regulators, including autoimmunity and neurodegeneration. The company partners with pharmaceutical and biotechnology organizations to advance therapeutics.
Founded: 2020
Headquarters: Seattle, WA
Focus: Drug discovery targeting transcription factors via regulome profiling
Platform: MARMOT native regulome profiling (functional proteomics + ML + chemistry)
Recent financing: Seed+ round led by Two Bear Capital (announced Aug 20, 2024)
| Company |
|---|
Drug discovery for diseases driven by genome regulators (oncology, rare disease, immune dysfunction, neurodegeneration).
2020
Biotechnology Research
9750000
Seed round closed; reported raise of $9.75M with participation from investors including NFX and Y Combinator.
11200000
Seed+ financing announced with participation from WRF Capital, NFX, YC Continuity Fund, FundersClub VC, and BoxOne Ventures.
“Two Bear Capital led the Aug 20, 2024 Seed+ round; earlier investors include NFX and Y Combinator.”
At Two Bear Capital we believe in partnering with our portfolio companies to find the best scientist possible and we look forward to working with you for Talus Bio's next Medicinal Chemist.
Fractional Medicinal Chemist (20–30% FTE)
About Talus Bio
Talus Bio is pioneering small-molecule therapeutics against previously “undruggable” transcription factors, combining covalent chemistry, proteomics, and computational/ML tools. As we advance two drug programs through hit-to-lead and lead optimization, we seek a seasoned medicinal chemist to provide strategic leadership and oversight of chemistry execution via CRO partnerships, while interfacing with our internal biology, proteomics, and computational teams.
Role Summary
We are looking for an experienced medicinal chemist to serve in a part-time, fractional capacity (20–30% effort), with responsibility for: guiding medicinal chemistry strategy across two programs, managing a ~10-person external chemistry team at a CRO, and integrating external chemistry work with internal discovery and computational efforts.
Key Responsibilities
Program Strategy & Drug Discovery
Qualifications & Experience
www.talus.bio
www.twobearcapital.com